This site has been optimized to work with modern browsers and does not fully support your version of Internet Explorer.

Oxford to lead global collaboration to research and develop next-generation COVID-19 and flu vaccines

The project is headed by Oxford University’s Professor Teresa Lambe OBE (Calleva Head of Vaccinology and Immunology, Department of Paediatrics) and co-developer of the Oxford/AstraZeneca COVID-19 vaccine and Paul Klenerman (Sidney Truelove Professor, Nuffield Department of Medicine)

  • £8 million funding from UKRI will catalyse global cooperation to improve understanding of existing COVID-19 vaccines and enhance future vaccine development
  • The research aims to enhance protection against several current and future respiratory pathogens – including COVID-19, flu and Respiratory Syncytial Virus (RSV) – contributing crucial new knowledge to future pandemic preparedness.

The University of Oxford has launched a new global collaboration backed by £8 million funding from UK Research and Innovation (UKRI). The research will better understand how through vaccination, the training and preservation of protective immune response can keep us safe from disease, contributing crucial new knowledge for future pandemic preparedness.

The consortium, made up of leading academic and industrial partners, will work on the development of better vaccines that will offer protection against multiple strains of COVID-19. The research aims to enhance protection against several respiratory pathogens, including influenza and Respiratory Syncytial Virus (RSV). The work will also establish global networks of trained personnel with the scientific tools to better prepare the world for the next pandemic.


Read the full story on the University of Oxford’s website.